| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/06/2000 | WO2000021988A3 Human ankyrin family protein |
| 07/06/2000 | WO2000021910A3 1,2-disubstituted cyclopropanes |
| 07/06/2000 | WO2000021512A3 Composition and method for treating allergic diseases |
| 07/06/2000 | WO2000020607A3 Chimaeric proteins between members of tgf-beta superfamily |
| 07/06/2000 | WO2000020591A3 Tgf-beta superfamily mutant members, including morphogenic proteins |
| 07/06/2000 | WO2000020025A3 Akt compositions for enhancing survival of cells |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000020020A3 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO2000014222A3 Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof |
| 07/06/2000 | WO2000013703A3 Methods of treating hypertension and compositions for use therein |
| 07/06/2000 | WO2000012509A3 Collections of compounds |
| 07/06/2000 | WO1999064035A9 β2-ADRENERGIC RECEPTOR AGONISTS |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | WO1999047655A3 Human nucleic acid fragments with heightened expression in normal breast tissue |
| 07/06/2000 | DE19860642A1 Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen An antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen-4 (VLA-4) in human cells |
| 07/06/2000 | CA2363999A1 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 07/06/2000 | CA2358687A1 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | CA2358315A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | CA2358091A1 Antithrombotic amides |
| 07/06/2000 | CA2358047A1 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds |
| 07/06/2000 | CA2357837A1 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 07/06/2000 | CA2356986A1 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356885A1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same |
| 07/06/2000 | CA2356838A1 Imidazole compounds and medicinal use thereof |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356692A1 Hydrophilic ampholytic polymer |
| 07/06/2000 | CA2356671A1 Protease inhibitors |
| 07/06/2000 | CA2356638A1 Indole and indolizidine derivatives for the treatment of migraine |
| 07/06/2000 | CA2356607A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356547A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 07/06/2000 | CA2356542A1 Peptidoglycan recognition proteins |
| 07/06/2000 | CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356424A1 Serine protease inhibitor |
| 07/06/2000 | CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2355744A1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2000 | CA2355281A1 Thrombin inhibitors |
| 07/06/2000 | CA2355096A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 07/06/2000 | CA2354052A1 Methods for treating certain diseases using naaladase inhibitors |
| 07/06/2000 | CA2351539A1 Method for preparing (r)- (+) -3 {1- ¬2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl|- 4-phenylpiperidin -4-yl}-1,1- dimethylurea, its salts solvates and/or hydrates |
| 07/06/2000 | CA2347671A1 Succinoylamino benzodiazepines as inhibitors of a.beta. protein production |
| 07/05/2000 | EP1016727A1 Gene therapy to promote angiogenesis. |
| 07/05/2000 | EP1016726A1 Gene therapy to promote angiogenesis |
| 07/05/2000 | EP1016716A2 Dna encoding a growth factor specific for epithelial cells |
| 07/05/2000 | EP1016415A2 Use of a fibrin glue for the regeneration of tissue |
| 07/05/2000 | EP1016414A2 Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans |
| 07/05/2000 | EP1016411A1 Sulodexide for restenosis therapy |
| 07/05/2000 | EP1016410A1 Glycosaminoglycans for the treatment for pre-eclampsia and related diseases |
| 07/05/2000 | EP1015884A1 Methods of identifying molecules that home to angiogenic vasculature in tumors |
| 07/05/2000 | EP1015607A1 Dna encoding a ras carboxyl-terminal processing protein |
| 07/05/2000 | EP1015587A1 DcR3 POLYPEPTIDE, A TNFR HOMOLOG |
| 07/05/2000 | EP1015586A2 Tie receptor tyrosine kinase ligand homologues |
| 07/05/2000 | EP1015585A2 Tie ligand homologues |
| 07/05/2000 | EP1015578A1 Therapeutic molecules |
| 07/05/2000 | EP1015566A1 Human ste20-like stress activated serine/threonine kinase |
| 07/05/2000 | EP1015559A1 Human regeneration-associated serpin-1 (rasp-1) and methods of use |
| 07/05/2000 | EP1015492A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 07/05/2000 | EP1015487A2 Ligands for discoidin domain receptor tyrosine kinases and complexes thereof |
| 07/05/2000 | EP1015474A1 Don-1 gene and polypeptides and uses therefor |
| 07/05/2000 | EP1015459A1 Tetrazole-containing rapamycin analogs with shortened half-lives |
| 07/05/2000 | EP1015458A1 Furopyrrolidine derivatives and their use as serine protease inhibitors |
| 07/05/2000 | EP1015456A1 Pyrrolopyrrolidine derivatives and their use as serine protease inhibitors |
| 07/05/2000 | EP1015455A1 Pyrrolopyrrolone derivatives |
| 07/05/2000 | EP1015454A1 Method of inhibiting serine protease enzymes |
| 07/05/2000 | EP1015449A1 (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors |
| 07/05/2000 | EP1015448A1 Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity: compounds, compositions and methods |
| 07/05/2000 | EP1015439A1 Prenyl transferase inhibitors |
| 07/05/2000 | EP1015438A1 Protease inhibitors |
| 07/05/2000 | EP1015427A1 Substituted 2-pyrrolidinone activators of pkc |
| 07/05/2000 | EP1015423A1 1,3-dihydroxy-20,20-dialkyl-vitamin d 3? analogs |
| 07/05/2000 | EP1015422A1 Hiv matrix protein tyrosine position 29 pocket binders |
| 07/05/2000 | EP1015417A1 Compounds containing six-membered rings, processes for their preparation, and their use as medicaments |
| 07/05/2000 | EP1015038A1 Methods for the detection, treatment, and prevention of neurodegeneration |
| 07/05/2000 | EP1015036A1 Improvements in or relating to expression of immunogenic substances |
| 07/05/2000 | EP1015031A1 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 07/05/2000 | EP1015029A1 Compound inhibiting presenilin 1 for preparing a medicine and a diagnostic agent |
| 07/05/2000 | EP1015021A2 Agents for combating bacterial meningitis |
| 07/05/2000 | EP1015019A1 Compositions and methods of therapy for igf-i-responsive conditions |
| 07/05/2000 | EP1015015A1 pRb2/p130 PEPTIDE INHIBITORS OF cdk2 KINASE ACTIVITY |
| 07/05/2000 | EP1015008A1 Compounds and compositions for delivering active agents |
| 07/05/2000 | EP1015007A1 Analogs of peptide yy and uses thereof |
| 07/05/2000 | EP1015006A2 Cocoa extract compounds and methods for making and using the same |
| 07/05/2000 | EP1014999A1 Cationic polymers as toxin-binding agents |
| 07/05/2000 | EP1014997A1 Substance and method for reduction of lipids and cholesterol |
| 07/05/2000 | EP1014996A1 Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
| 07/05/2000 | EP1014994A1 Phosphono-carboxylate compounds for treating amyloidosis |
| 07/05/2000 | EP1014989A1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 07/05/2000 | EP1014986A1 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST |
| 07/05/2000 | EP1014984A1 Inhibitors of prenyl-protein transferase |
| 07/05/2000 | EP1014982A1 Troglitazone compounds for treating climacteric |
| 07/05/2000 | EP1014981A1 Pharmaceutical composition for treatment of synaptic dysfunction comprising an oxime |
| 07/05/2000 | EP1014978A1 Method of using neutrophic sulfonamide compounds |
| 07/05/2000 | EP1014976A1 Novel substituted imidazole compounds |